Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma

Trial Profile

Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Baltaleucel-T (Primary)
  • Indications Epstein-Barr virus infections; Hodgkin's disease; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms GRALE
  • Most Recent Events

    • 06 Dec 2016 Results of two studies (CITADEL and GRALE) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 24 Jul 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 24 Jul 2015 Planned End Date changed from 1 Dec 2020 to 1 Jul 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top